Sector Watch: Healthcare - May 04 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $102.35 +1.07 1.06% | XBI: $87.37 +1.45 1.69% | Updated May 04, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| PTLA Portola Pharmaceuticals $2.9B |
42.44+8.66 10.6 M 11.0x |
26% | ||
| RNN Rexahn Pharmaceuticals $69.8M |
2.21+0.40 2.8 M 11.2x |
22% | ||
| SRPT52WH Sarepta Therapeutics $5.9B |
89.75+11.58 5.7 M 5.3x |
15% | ||
| ESPR Esperion Therapeutics $1.4B |
41.54+4.61 5.3 M 3.7x |
12% | ||
| PFNX Pfenex $146.8M |
6.01+0.66 71.3 K |
12% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| CHEK Check-Cap $121.6M |
4.55-4.26 2.8 M 3.4x |
-48% | ||
| ADVM Adverum Biotechnologies $331.1M |
5.32-1.03 3.5 M 6.3x |
-16% | ||
| LNTH Lantheus Holdings $649.7M |
16.42-1.48 761.4 K 2.0x |
-8% | ||
| NKTR Nektar Therapeutics $12.8B |
77.20-5.55 3.9 M 1.8x |
-7% | ||
| IVTY52WL Invuity $72.1M |
2.80-0.20 907.9 K 4.3x |
-7% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
Check-Cap Announces Pricing of $17.5 Million Upsized Underwritten Public Offering [globenewswire.com]U.S. FDA Approves Portola Pharmaceuticals? Andexxa®, First and Only Antidote for the Reversal of Factor Xa Inhibitors [globenewswire.com]
Adverum Biotechnologies Announces Leadership Changes [globenewswire.com]
Sarepta Therapeutics Announces Partnership with Myonexus Therapeutics for the Advancement of Multiple Gene Therapy Programs Aimed at Treating Distinct Forms of Limb-Girdle Muscular Dystrophies [globenewswire.com]
Sarepta Therapeutics Announces First Quarter 2018 Financial Results and Recent Corporate Developments [globenewswire.com]
New Research: Key Drivers of Growth for Hospitality Properties Trust, Shell Midstream Partners, Archrock, Phillips 66 Partners LP, Lantheus, and Kindred Healthcare ? Factors of Influence, Major Initiatives and Sustained Production [globenewswire.com]
Important Stock Score Report Updates for Esperion Therapeutics, Integrated Media Technology, [prnewswire.com]
Nektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After [prnewswire.com]
Important Stock Score Report Updates for Esperion Therapeutics, Integrated Media Technology, Mastercard, Molson Coors, and Wayfair [prnewswire.com]
Nektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial Markets [prnewswire.com]
Stock Review for Biotech?s Investors -- BioTime, Eleven Biotherapeutics, Endocyte, and Esperion [prnewswire.com]
Stock Review for Biotech's Investors -- BioTime, Eleven Biotherapeutics, Endocyte, and Esperion Therapeutics [prnewswire.com]
Lantheus Holdings, Inc. Reports 2018 First Quarter Results | Business Wire [businesswire.com]
Factors of Influence in 2018, Key Indicators and Opportunity within Independent Bank Group, Eclipse Resources, Stellus Capital Investment, International Bancshares, Portola Pharmaceuticals, and Revance Therapeutics ? New Research Emphasizes Economic Growth [globenewswire.com]
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports First Quarter 2018 Financial Results [globenewswire.com]
Esperion Announces Positive Top-Line Results from Pivotal Phase 3 Long-Term Safety Study of Bempedoic Acid [globenewswire.com]
Adverum Biotechnologies Announces Long-term Preclinical Efficacy Data on ADVM-022 Gene Therapy in Wet AMD [globenewswire.com]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [globenewswire.com]
Portola Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018 [globenewswire.com]
Pfenex to Report First Quarter 2018 Results and Provide Business Update on Thursday, May 10th [prnewswire.com]
Apixaban Market Extensive Analysis of Supply And Demand, Revenue, Risk and Share 2018-2025 [prnewswire.com]
Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting [prnewswire.com]
Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex, Stoneridge, and First Interstate BancSystem ? Discovering Underlying Factors of Influence [globenewswire.com]
Biotech Stocks? Research Reports Released on Pieris Pharma, Portola Pharma, Protalix [prnewswire.com]
Biotech Stocks' Research Reports Released on Pieris Pharma, Portola Pharma, Protalix BioTherapeutics, and Radius Health [prnewswire.com]
Rexahn to Present Clinical Data at 2018 American Society of Clinical Oncology (ASCO) Annual Meeting [globenewswire.com]
Bristol-Myers Squibb Reports First Quarter Financial Results | Business Wire [businesswire.com]
Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting [globenewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
